By Fineline Cube Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that the U.S. Food and Drug Administration (FDA) has approved its clinical trial application for 6MW5311 for injection, a LILRB4/CD3 bispecific antibody (BsAb) developed for the treatment of hematologic malignancies including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). Additionally, the National Medical Products Administration (NMPA) in China has accepted the clinical trial application for review.
Regulatory Milestone
| Jurisdiction | Agency | Status | Indication |
|---|---|---|---|
| United States | FDA | Approved | AML, CMML, MM |
| China | NMPA | Under Review | AML, CMML, MM |
Drug Profile & Mechanism of Action
- Molecule: LILRB4/CD3 bispecific antibody (BsAb)
- Platform: Developed on Mabwell’s proprietary T cell engager (TCE) technology platform
- Mechanism: Bridges tumor cells and T cells to form an immune synapse, activating T cells and efficiently killing tumor cells
- Target Population: Patients with hematologic malignancies (AML, CMML, MM)
- Development Stage: Phase I clinical trials pending initiation
Preclinical Evidence
| Parameter | Result |
|---|---|
| Tumor Inhibition | Significant anti-tumor activity demonstrated across multiple hematologic cancer models |
| Safety Profile | Favorable toxicity profile with no severe adverse events in preclinical studies |
| Target Specificity | High specificity for LILRB4-expressing tumor cells with minimal off-target effects |
| T Cell Activation | Robust T cell activation and cytokine release at therapeutic concentrations |
Strategic Significance
This dual regulatory progress positions 6MW5311 as a potential first-in-class LILRB4/CD3 bispecific antibody for hematologic malignancies. The simultaneous advancement in both U.S. and Chinese markets reflects Mabwell’s global development strategy and the significant unmet medical need in these difficult-to-treat blood cancers.
Market Context & Competitive Landscape
- AML Market: Global AML therapeutics market projected to reach $3.2 billion by 2028, with limited effective treatments for relapsed/refractory cases
- Bispecific Antibody Trend: Growing interest in T cell-engaging bispecific antibodies following successes in other hematologic indications
- LILRB4 Target: Emerging target with high expression in AML and other myeloid malignancies, offering potential for improved specificity over current therapies
- Competitive Position: Among the first LILRB4-targeting bispecific antibodies to enter clinical development globally
Next Steps & Timeline
- U.S. Trial Initiation: Phase I dose-escalation study expected to begin Q4 2026
- Chinese Trial Timeline: Dependent on NMPA review completion, anticipated early 2027
- Primary Endpoints: Safety, tolerability, maximum tolerated dose, and preliminary efficacy
- Global Development: Potential for accelerated pathways based on orphan drug designations in both jurisdictions
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive developments.-Fineline Info & Tech